MedTrace Logo

A Registry Study of Participants With Multiple Myeloma in Latin America

NCT03955900 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2059

Last updated 2023-03-07

No results posted yet for this study

Summary

The purpose of this study is to characterize the multiple myeloma (MM) population concerning demographics and clinical characteristics (for example. frailty, risk strata, manifestations of target organ damage \[TOD\]) in 6 countries (that is Argentina, Brazil, Mexico, Chile, Colombia and Panama); and to profile the treatment landscape of Latin American MM participants, including factors associated with health-care provider (HCP) selections of different treatment regimens. These factors can include a participant's demographic and clinical characteristics and availability of different therapy options per institution in each country.

Conditions

Interventions

OTHER

No intervention

Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Ltd. Clinical Trial · Janssen-Cilag Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-29
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Argentina
  • Brazil
  • Colombia
  • Mexico
  • Panama

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03955900 on ClinicalTrials.gov